Commercial Success of ADHD Drug
This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Background
A number of generic drug companies sought FDA approval to market generic versions of a branded ADHD drug prior to the expiration of patents covering the branded drug. The generic drug companies filed Abbreviated New Drug Applications and Paragraph IV certifications asserting that patents covering the branded drug were invalid or not infringed. In response, the branded drug company filed claims of patent infringement against the generic drug companies.
Our Analysis
Intensity provided an expert report, deposition testimony, and trial testimony relating to an evaluation of the commercial success of patents covering the branded drug. As part of addressing patent validity, the court considered the testimony of a Intensity expert on whether the patented invention had been a commercial success.
Intensity analyzed economic issues involving market definition, commercial performance, and long-felt need in the marketplace. Intensity performed economic analysis to evaluate sales and market share of the branded drug among competing drugs in the marketplace. In addition, we organized and processed complex data and presented its findings from the data analysis at trial.
Intensity analyzed a number of economic issues to inform on whether commercial performance of the branded drug was driven by the patents-in-suit or other economic factors. These issues included pricing, discounting, profitability, marketing, and other potential drivers of sales. Intensity also evaluated the economic impact of marketing materials that FDA had found to be false and misleading to consumers.
Latest Insights
News | September 8, 2025
Navigating New Rules of the Road: How Companies Can Adapt to Revised DOJ Guidance on Criminal Prosecutions
Since the election in November 2024, there have been many changes to DOJ’s enforcement policies. Earlier this year, now-Acting Assistant Attorney General of the Criminal Division, Matthew R. Galeotti, announced at the Securities Industry and Financial Markets Association (SIFMA), that going forward prosecutors and investigators would primarily focus on “the most egregious white-collar crime” to better “incentivize [companies] to come forward, come clean, reform, and cooperate with the government.”
Article | August 19, 2025
Overtaken by Events: What Delay Quantification Can Tell Us About Causality
In the International Construction Law Review, Stuart Jones presents an innovative approach to delay analysis in construction disputes. His article, “Overtaken by Events: What Delay Quantification Can Tell Us About Causality,” introduces a forensic and mathematical framework that challenges conventional assumptions about project delay and causation.
See All Insights
Talk to Our Insightful Experts